Jose Llinas Cepeda, MD
Endocrinology, Diabetes & Metabolism · Edinburg, TXNPI 1164652533
Payments from drug & device makers
Across 610 payments — averaging $222.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$117K
- Mannkind Corporation$8K
- Tandem Diabetes Care, Inc.$2K
- Dexcom, Inc.$2K
- Ascensia Diabetes Care US Inc.$2K
- Abbott$1K
- plus $4K from 32 others
What the payments were for
- Consulting fees$6,2055%
- Speaking & faculty fees$100,08674%
- Travel & lodging$12,7779%
- Food & beverage$16,65312%
- Education$2040%
- Gifts$590%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 267 | $116,790 |
| Mannkind Corporation | 29 | $8,086 |
| Tandem Diabetes Care, Inc. | 6 | $1,938 |
| Dexcom, Inc. | 56 | $1,804 |
| Ascensia Diabetes Care US Inc. | 30 | $1,711 |
| Abbott | 35 | $1,209 |
| Amgen(2 entities) | 34 | $614 |
| Insulet Corporation | 9 | $472 |
| Lilly USA, LLC | 22 | $425 |
| AstraZeneca(2 entities) | 15 | $412 |
| Corcept Therapeutics | 15 | $363 |
| Radius Health, Inc. | 22 | $331 |
| Novartis | 10 | $209 |
| Boehringer Ingelheim | 9 | $170 |
| Intuity Medical Inc | 3 | $146 |
| Sanofi-aventis U.S. LLC | 7 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $134 |
| Merz North America, Inc. | 1 | $119 |
| Madrigal Pharmaceuticals | 1 | $107 |
| AbbVie(2 entities) | 4 | $93 |
| Xeris Pharmaceuticals, Inc. | 5 | $92 |
| Medtronic | 2 | $82 |
| Cequr Corporation | 3 | $76 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 3 | $54 |
| Antares Pharma, Inc. | 3 | $53 |
| Senseonics, Incorporated | 1 | $44 |
| Amryt Pharma Holdings Ltd | 2 | $40 |
| Bayer | 2 | $34 |
| Sandoz | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| BD | 1 | $25 |
| Chiesi USA, Inc. | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| BETA Bionics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$54,844
- RYBELSUS$41,686
- AFREZZA$7,465
- Victoza$5,137
- t:slim X2 Insulin Pump with Control-IQ$1,771
- EVERSENSE E3 SENSOR KIT - RETAIL$624
- DEXCOM G6 TRANSMITTER$571
- FreeStyle Libre$299
- Omnipod$266
- EVERSENSE 365 SENSOR KIT (RETAIL)$229
- FREESTYLE LIBRE 3$135
- CRENESSITY$134
- FreeStyle Libre 2$128
- Pogo Automatic Blood Glucose Monitoring System$126
- V-GO$125
- Tresiba$125
- Xultophy 100/3.6$125
- Korlym$115
- FARXIGA$115
- REZDIFFRA$107
How this compares
$136,011 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 503 | $807,549 |
| KorlymMifepristone | 15 | $604,502 |
| MounjaroTirzepatide | 318 | $466,532 |
| FarxigaDapagliflozin Propanediol | 161 | $167,327 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 129 | $143,496 |
| Tresiba Flextouch U-200Insulin Degludec | 152 | $136,682 |
| MycapssaOctreotide Acetate | 12 | $106,085 |
| JardianceEmpagliflozin | 81 | $103,800 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 83 | $96,547 |
| TrulicityDulaglutide | 64 | $96,441 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $72,561 |
| TymlosAbaloparatide | 19 | $58,493 |
| RybelsusSemaglutide | 38 | $55,989 |
| JanuviaSitagliptin Phosphate | 46 | $48,280 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $43,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $116,790 | $863,538541 claims |
| Corcept TherapeuticsKorlym | $363 | $604,50215 claims |
| Lilly USA, LLCMounjaro, Trulicity | $425 | $562,973382 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Trijardy Xr, Glyxambi | $170 | $379,134326 claims |
| AstraZenecaFarxiga | $412 | $167,327161 claims |
| Chiesi USA, Inc.Mycapssa | $25 | $106,08512 claims |
| AmgenProlia, Evenity (2 Syringes) | $614 | $67,61933 claims |
| Radius Health, Inc.Tymlos | $331 | $58,49319 claims |
| AbbVieLinzess | $93 | $11,61012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Edinburg
- Eduardo LunaEdinburg$7.6M
- Alejandro Gonzalez CamposEdinburg$694K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.